Singapore, June 13 -- Cytiva, a Danaher company and global life sciences leader, has completed significant expansion projects in several locations in the United States, Europe, and Asia as part of its ongoing commitment to enhancing delivery for customers developing and manufacturing advanced therapeutics. Set to continue through 2028, these expansions will meet increased customer demand as part of Cytiva's long-term growth plan and in-region manufacturing strategy, supported by an investment of $1.6 billion since 2019.

The latest investments in chromatography resins and filtration include:

The start of filtration manufacturing at Cytiva's Innovation Hub and manufacturing facility in South Korea in 2026to address increased demand for hi...